Stargardt Disease clinical trials at UCSF

• Safety and Efficacy of Emixustat in Stargardt Disease

  Sorry, in progress, not accepting new patients

  The purpose of this study is to determine if emixustat hydrochloride reduces the rate of progression of macular atrophy compared to placebo in subjects with Stargardt disease. Funding Source -- FDA OOPD

  San Francisco, California and other locations

Last updated: August 27, 2020